1.6500
22-11月-24 16:44:58
15 分の遅延
株式
+0.0500
+3.12%
本日の幅
1.5800 - 1.6800
ISIN
N/A
ソース
NASDAQ
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 4 2024 07:00:00 提供 Nasdaq GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 3 2024 07:06:46 提供 Nasdaq GlobeNewswire